Please assess the completion status of the following clinical trial:

Trial Title: A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reasonably healthy men and women aged 50 to 75~Exclusion Criteria:~* History of abnormal bleeding, active bleeding or risk factors for bleeding~* History of thrombosis or risk factors for thrombosis~* History of adult asthma or use of inhaled medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Andexanet 800mg bolus (Part I) (Type: EXPERIMENTAL): Andexanet (antidote) - 800 mg bolus
- Andexanet 800mg + 960mg (Part II) (Type: EXPERIMENTAL): 800 mg bolus + 960 mg infusion (8 mg/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).